From Penn Medicine News:
Liver cancer screening among patients with cirrhosis almost doubled when they were mailed a signed order from their specialist, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. However, when researchers added an incentive of $20 to the mailed orders, it made no difference in whether patients completed their screenings. The work was published this week in Hepatology Communications.
“Our findings show that an approach like this can meaningfully increase liver cancer surveillance, which is particularly important in a group of patients who are high risk for liver cancer,” said Shivan Mehta, MD, MBA, an associate professor of Gastroenterology and the associate chief innovation officer at Penn Medicine.